New Cancer Drug Fund (CDF) guidance issued in January 2026 means more patients could be eligible for adjuvant treatment with combined Olaparib and hormone therapy. Aligned with this, eligibility criteria for genetic test R444 (NICE approved PARP inhibitor treatment) has been updated.
View the CDF January 2026 update
Full information on CDF funding for Olaparib in combination with hormone therapy (OLAP6)
Summary of R444 eligibility criteria:
For people with hormone receptor-positive, HER2-negative breast cancer who have received neoadjuvant chemotherapy and have residual invasive cancer in the breast or the resected lymph nodes (non-pathologic complete response) or both at the time of surgery, testing is now available where there is either a diagnostic or surgical specimen which is confirmed as pathological high grade.
For people with hormone receptor-positive, HER2-negative breast cancer having adjuvant chemotherapy, testing is now available where there is a pre-chemotherapy pathological demonstration of at least one positive lymph node.
These represent changes to the 3rd and 4th eligibility criteria for R444.1 in the national genomic test directory (opens in a new tab).
Please review the eligibility criteria document before ordering.
For guidance on R444 ordering, contact us.